Agios Pharmaceuticals Biotech News Portfolio

Agios Pharmaceuticals: FDA Breakthrough Therapy Designation for Tibsovo in Myelodysplastic Syndrome

Biotech News | 18.12.2019

Agios Pharmaceuticals’ cancer drug Tibsovo is granted FDA breakthrough therapy designation for...

Agios Pharmaceuticals Portfolio Stock Recommendations

Agios Pharmaceuticals: Buy! One of the Top Biotech Stocks!

Biotech News | 26.10.2019

Since the beginning of April 2019, the stock of Agios Pharmaceuticals has known only one direction:...

Agios Pharmaceuticals Biotech News Portfolio

Agios’ Drug Tibsovo Prolongs Progression-Free Survival in Phase 3 Cholangiocarcinoma Trial by only 2 Months, Shares Down by 6%

Biotech News | 30.09.2019

Agios Pharmaceuticals today announced the presentation of phase 3 clinical trial data for Tibsovo....

Agios Pharmaceuticals Biotech News Portfolio

Encouraging Second Quarter for Agios Pharmaceuticals: IDH inhibitor Tibsovo Shows Strong Growth

Biotech News | 01.08.2019

Agios Pharmaceuticals, a company specializing in the development of oncology and rare genetic...